Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Plaque Clear all
Completed Phase 3 Interventional Results available

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

NCT05272150
View directory record Official record
Conditions
Plaque Psoriasis, Scalp Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam

NCT00436540
View directory record Official record
Conditions
Psoriasis
Interventions
Clobetasol Propionate 0.05% Spray, Clobetasol Propionate 0.05% Foam
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Vallejo, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 22, 2026, 10:58 AM EDT
Completed No phase listed Observational

Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome

NCT03479723
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jul 22, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects

NCT00605046
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SPECT scan
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT01483924
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apo805K1
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

NCT02074982
View directory record Official record
Conditions
Chronic Plaque Type Psoriasis
Interventions
AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 22, 2026, 10:58 AM EDT
Terminated No phase listed Observational

Role of Insulin Action in Psoriasis Pathogenesis

NCT06242847
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
Interventions
Oral glucose tolerance test (OGTT), Skin punch biopsy
Diagnostic Test · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

NCT03635099
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

NCT01096862
View directory record Official record
Conditions
Psoriasis
Interventions
peficitinib, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 22, 2026, 10:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
50
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Analysis of Small and Large Plaque Psoriasis

NCT01920906
View directory record Official record
Conditions
Psoriasis
Interventions
Skin biopsy and blood test
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00195676
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
66
States / cities
Birmingham, Alabama • Buckner 13075 PI, Alabama • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

NCT00439010
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123I] AV 39
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2008 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting Phase 4 Interventional

Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis

NCT07614490
View directory record Official record
Conditions
Gingivitis, Plaque
Interventions
sodium monofluorophosphate toothpaste
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Effectiveness of an Experimental Toothpaste in Improving Gum Health and Reducing Plaque Accumulation

NCT07255040
View directory record Official record
Conditions
Dental Plaque, Gingivitis
Interventions
Test Dentifrice, Parodontax Complete Protection, Colgate Cavity Protection
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Light Treatment Effectiveness (LITE) Study

NCT03726489
View directory record Official record
Conditions
Psoriasis, Psoriatic Plaque
Interventions
Daavlin 7 series 3 panel narrow band phototherapy home units, narrow band phototherapy clinic units
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
12 Years and older
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

NCT01043393
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.25% spray
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Hot Springs, Arkansas • Albuquerque, New Mexico • Simpsonville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Atorvastatin on Atherosclerosis Composition

NCT00576576
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885
View directory record Official record
Conditions
Psoriasis
Interventions
D-2570 Tablet, Placebo Tablets
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

NCT00601107
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Doxercalciferol, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis

NCT01107457
View directory record Official record
Conditions
Psoriasis
Interventions
Ixekizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
31
States / cities
Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

4-day Plaque Accumulation Model Evaluating Compound Containing Gum

NCT06984744
View directory record Official record
Conditions
Dental Plaque Accumulation
Interventions
MIIP-E2 containing gum, placebo gum without MIIP-E2
Device
Lead sponsor
Lactea Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 22, 2026, 10:58 AM EDT